The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/197672

Please be advised that this information was generated on 2019-04-07 and may be subject to change.
Dissemination of localized Mycobacterium malmoense infection in an immunocompromised patient

A 75-year-old woman with a history of immunosuppressive treatment for rheumatoid arthritis and non-Hodgkin lymphoma, was referred to our reference centre for treatment of tenosynovitis caused by Mycobacterium malmoense, which had disseminated due to immunosuppressive therapy. This rare diagnosis was made after years of treatment for supposed rheumatoid arthritis. The patient presented with relapsing tenosynovitis with wounds on her right middle finger and wounds on her left lower leg, despite 3 months of adequate therapy (rifampicin + ethambutol + clarithromycin). Therapy was intensified with amikacin, clofazimine, moxifloxacin, and interferon-gamma due to the lack of response. Amputation of the right middle finger was necessary due to advanced disease. Treatment was further complicated by a paradoxical reaction, requiring prednisone treatment, which ultimately led to cure.

© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
syndrome. Eventually, amputation of the right middle finger was performed. Histology of the amputated finger showed granulomatous inflammation with acid-fast rods in auramine stains.

A paradoxical reaction was considered as a possible explanation for the lack of improvement. Prednisone (starting dose of 1 mg/kg, follow by a slow tapered schedule) was given and led to rapid marked improvement of the patient's clinical signs and symptoms. After almost 4 months, prednisone could be stopped, as follow-up PET-CT imaging confirmed the decrease in severity of inflammation.

Due to adverse events, consisting of cutaneous reactions, antimycobacterial drugs were halted after 9 months. As immunomodulatory treatment had been halted and the paradoxical reaction had waned, it was estimated that the treatment had been of a sufficient duration. One year after cessation of antibiotics, the patient has not had a recurrence of *M. malmoense* disease.

**Discussion**

This patient was suffering from relapsing tenosynovitis for years. This was at first attributed to rheumatoid arthritis, although different treatments did not have the desired effect. Eventually, the diagnosis of disseminated *M. malmoense* infection was made.

Based on the lack of response to all of the different treatments given for rheumatoid arthritis, it is hypothesized that *M. malmoense* tenosynovitis was the most likely diagnosis from the beginning and that the patient probably had not suffered from rheumatoid arthritis. Yet, with the many injections and wounds present over time, *M. malmoense* may also have been inoculated later in the course of disease.

Due to the immunomodulatory medication use, the mycobacterial disease had the opportunity to disseminate. After interrupting the immunosuppressive drugs and starting the antimycobacterial drugs, the immune system recovered and different lesions at sites to which *M. malmoense* had spread became apparent. This was first interpreted as a poor clinical response, but eventually as a paradoxical reaction. As a result, prednisone was started, which had a good effect. Although paradoxical reactions are well described in the treatment of tuberculosis (Melboucy-Belkhir et al., 2010), almost no case reports on non-tuberculous mycobacteria (NTM) are available. Theoretically, a similar paradoxical response as seen in tuberculosis could be expected in the treatment of NTM as well. In this case, the cessation of anti-inflammatory drugs used for rheumatoid arthritis might have contributed to the paradoxical response.

As a differential diagnosis, Poncelet’s disease was also considered. Poncelet’s disease was first described in tuberculosis patients in 1897. It is a rare presentation of reactive polyarthritis, without mycobacterial involvement of the joint. After infection, as a result of systemic immunization, sensitized CD4+ cells together with bacterial antigens migrate to the joints and cause arthritis (Sharma et al., 2016). In the case presented herein, the positive cultures eventually ruled out Poncelet’s disease.

The incidence of *M. malmoense* infections has increased since 1980, especially in northern Europe (Hoefsloot et al., 2008). Pulmonary infections are the most frequent disease manifestation (Hoefsloot et al., 2009). Extrapulmonary *M. malmoense* infection is rare, except for lymphadenitis in children and tenosynovitis (Hoefsloot et al., 2008). Dissemination is only observed in patients with severely impaired immunity (Zaugg et al., 1993). In this case,
the patient had multiple causes of impaired immunity, not only due to immunosuppressive medication, but also due to for instance non-Hodgkin lymphoma.

The diagnosis of *M. malmoense* disease was further complicated by the fact that *M. malmoense* is a slow-growing Mycobacterium that can take up to 8 weeks to grow in mycobacterial culture. Supplementing the medium with pyruvate and acidification of the medium to a pH of 6 can help to increase the growth rate of *M. malmoense* and ensure its detection (Katila et al., 1989). Direct detection of NTM in clinical samples by molecular techniques can further increase the sensitivity of mycobacterial diagnostics (Deggim-Messmer et al., 2016).

In conclusion, immunosuppressive medication can cause dissemination of otherwise localized infections with *M. malmoense*. The diagnosis and treatment of *M. malmoense* tenosynovitis can be challenging. Paradoxical reactions should be considered in the case of treatment failure.

Funding source

There was no funding for this research.

Ethical approval

No ethical approval was required as it is a case report.

Conflict of interest

Wouter Hoefsloot and Sanne Zweijpfenning have received funding for other non-related research from Insmed.

References


Sanne M.H. Zweijpfenninga,*
Lydia Schipperb
Vincent A.M. Duurkensc
Joop B. Harbersd
Jakko van Ingenb
Wouter Hoefsloota

aRadboud University Medical Centre Dekkerswald, Department of Pulmonary Diseases, PO Box 9101, 6500HB Nijmegen, The Netherlands

bRadboud University Medical Centre, Department of Rheumatology, PO Box 9101, 6500HB Nijmegen, The Netherlands

Bravis Hospital, Department of Pulmonary Diseases, Boerhaaveplein 25, Postbus 999, 4700AZ Roosendaal, The Netherlands

Bravis Hospital, Department of Rheumatology, Boerhaaveplein 1, Postbus 135, 4600AC Bergen op Zoom, The Netherlands

cRadboud University Medical Centre, Department of Medical Microbiology, PO Box 9101, 6500HB Nijmegen, The Netherlands

* Corresponding author.

E-mail address: sanne.zweijpfenning@radboudumc.nl (S. Zweijpfenning).

Corresponding Editor: Eskild Petersen, Aarhus, Denmark

Received 23 July 2018
Received in revised form 22 August 2018
Accepted 30 August 2018